ALDX net incomeQ3 2026-$3.76M
ALDX net income was -$3.76M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.69M a year earlier. For the full fiscal 2025 it was -$33.85M, compared with -$55.85M in fiscal 2024.
Aldeyra Therapeutics Inc. (ALDX) financials
For the twelve months ended Sep 30, 2026, Aldeyra Therapeutics Inc. reported -$19.13M of net income.
- Net income, TTM
- -$19.13M
- EPS, diluted, TTM
- -$0.31
- Cash
- $40.97M
- Market cap
- $38.9M
FY2016FY2025
FY2016FY2023
ALDX revenue and earnings growth
ALDX EPSQ3 2026-$0.06
ALDX diluted EPS was -$0.06 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.13 a year earlier. For the full fiscal 2025 it was -$0.56, compared with -$0.94 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $25.66M | $48.22M | $29.46M | $47.31M | $44.94M | $24.68M | $44.35M | $29.82M | $16.30M | $13.18M |
| Selling, general and admin | $9.60M | $11.89M | $13.34M | $15.37M | $11.28M | $9.99M | $12.15M | $9.88M | $6.19M | $5.52M |
| Operating income | -$35.27M | -$60.12M | -$42.79M | -$62.68M | -$56.22M | -$36.42M | -$63.07M | -$39.70M | -$22.49M | -$18.70M |
| Interest expense | $1.91M | $1.93M | $2.07M | $1.69M | $1.74M | $1.90M | $603.8K | $146.8K | $113.5K | $105.5K |
| Pre-tax income | - | - | - | - | -$57.78M | -$38.03M | -$62.14M | -$38.89M | - | - |
| Income tax | $0 | $1.0K | $0 | $0 | $0 | -$479.3K | -$1.31M | $0 | $0 | $0 |
| Net income | -$33.85M | -$55.85M | -$37.54M | -$62.02M | -$57.78M | -$37.55M | -$60.83M | -$38.89M | -$22.34M | -$18.70M |
| EPS, basic | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | -$1.11 | -$2.24 | -$1.79 | -$1.40 | -$1.65 |
| EPS, diluted | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | -$1.11 | -$2.24 | -$1.79 | -$1.40 | -$1.65 |
| Diluted shares | 60.1M | 59.5M | 58.9M | 58.4M | 54.0M | 34.0M | 27.1M | 21.7M | 15.9M | 11.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $70.04M | $54.53M | $142.82M | $144.42M | $229.79M | $77.86M | $44.43M | $47.36M | $20.02M | $12.02M |
| Short-term investments | - | $46.62M | - | $29.88M | - | - | - | - | - | - |
| Current assets | $71.78M | $104.07M | $147.81M | $181.02M | $232.75M | $83.06M | $75.17M | $94.77M | $43.97M | $25.13M |
| Total assets | $72.06M | $104.61M | $148.33M | $181.29M | $233.14M | $83.35M | $75.52M | $95.09M | $44.17M | $25.19M |
| Current liabilities | $27.81M | $18.60M | $22.26M | $15.36M | $11.77M | $12.41M | $12.91M | $8.47M | $3.35M | $2.30M |
| Short-term debt | $15.25M | $31.4K | $15.15M | $911.8K | - | - | - | - | $116.3K | $77.5K |
| Long-term debt | $0 | $15.00M | $0 | $14.92M | $15.50M | $11.43M | $14.53M | - | $1.22M | $1.24M |
| Total debt | $15.25M | $15.03M | $15.15M | $15.83M | $15.50M | $11.43M | $14.53M | $16.04M | $1.34M | $1.32M |
| Total liabilities | $27.81M | $33.60M | $28.53M | $30.28M | $27.40M | $23.84M | $27.44M | $8.47M | $4.57M | $3.54M |
| Shareholders' equity | $44.25M | $71.00M | $119.80M | $151.01M | $205.74M | $59.51M | $48.08M | $86.62M | $39.60M | $21.65M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.35M | -$43.21M | -$30.33M | -$56.64M | -$42.56M | -$37.49M | -$44.98M | -$29.86M | -$19.22M | -$15.15M |
| Capital expenditures | - | - | $0 | $16.3K | $7.8K | - | $9.5K | $263.0K | $24.8K | $11.8K |
| Free cash flow | - | - | -$30.33M | -$56.65M | -$42.56M | - | -$44.99M | -$30.12M | -$19.25M | -$15.16M |
| Investing cash flow | $47.74M | -$44.92M | $30.00M | -$29.95M | -$7.8K | $29.02M | $18.48M | -$23.34M | -$10.20M | -$225.2K |
| Financing cash flow | $1.12M | -$171.4K | -$1.27M | $1.22M | $194.50M | $41.90M | $23.58M | $80.53M | $37.43M | $12.74M |
| Stock-based compensation | $6.09M | $7.97M | $5.75M | $8.29M | $7.11M | $7.08M | $8.08M | $4.14M | $2.71M | $2.76M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -76.5% | -78.7% | -31.3% | -41.1% | -28.1% | -63.1% | -126.5% | -44.9% | -56.4% | -86.4% |
| Return on assets | -47.0% | -53.4% | -25.3% | -34.2% | -24.8% | -45.1% | -80.5% | -40.9% | -50.6% | -74.2% |
| Current ratio | 2.58 | 5.59 | 6.64 | 11.78 | 19.77 | 6.69 | 5.82 | 11.18 | 13.11 | 10.93 |
| Debt to equity | 0.34 | 0.21 | 0.13 | 0.10 | 0.08 | 0.19 | 0.30 | 0.19 | 0.03 | 0.06 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.84M | $3.48M | $2.41M | $4.30M | $5.43M | $8.51M | $7.42M | $14.63M | $12.44M | $14.97M | $6.18M | $4.30M |
| Selling, general and admin | $2.30M | $2.37M | $1.14M | $2.36M | $2.57M | $1.66M | $3.00M | $1.95M | $3.70M | $3.04M | $3.21M | $1.80M |
| Operating income | -$4.14M | -$5.85M | -$3.55M | -$6.67M | -$8.00M | -$10.17M | -$10.43M | -$16.58M | -$16.14M | -$18.01M | -$9.39M | -$6.10M |
| Interest expense | $438 | $23 | $468.7K | $475.3K | $475.9K | $470.6K | $483.5K | $470.9K | $479.3K | $477.6K | $498.5K | $514.3K |
| Net income | -$3.76M | -$5.45M | -$3.45M | -$6.46M | -$7.69M | -$9.77M | -$9.93M | -$15.81M | -$15.11M | -$16.85M | -$8.08M | -$4.75M |
| EPS, basic | -$0.06 | -$0.09 | -$0.06 | -$0.10 | -$0.13 | -$0.16 | -$0.17 | -$0.27 | -$0.25 | -$0.28 | -$0.14 | -$0.08 |
| EPS, diluted | -$0.06 | -$0.09 | -$0.06 | -$0.10 | -$0.13 | -$0.16 | -$0.17 | -$0.27 | -$0.25 | -$0.28 | -$0.14 | -$0.08 |
| Diluted shares | 60.4M | 60.3M | 60.3M | - | 60.1M | 60.0M | 59.9M | - | 59.5M | 59.4M | 59.4M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $40.97M | $45.09M | $65.00M | $70.04M | $59.34M | $41.24M | $50.35M | $54.53M | $68.12M | $71.03M | $102.49M | $142.82M |
| Short-term investments | - | - | - | - | $15.96M | $40.68M | $39.71M | $46.62M | $44.62M | $49.30M | $30.55M | - |
| Current assets | $42.92M | $47.38M | $66.27M | $71.78M | $77.46M | $84.56M | $92.73M | $104.07M | $116.72M | $125.65M | $140.85M | $147.81M |
| Total assets | $43.38M | $47.54M | $66.48M | $72.06M | $77.80M | $84.96M | $93.20M | $104.61M | $117.32M | $126.04M | $141.30M | $148.33M |
| Current liabilities | $7.88M | $9.66M | $24.33M | $27.81M | $28.48M | $29.53M | $14.29M | $18.60M | $17.15M | $27.59M | $21.68M | $22.26M |
| Short-term debt | $0 | $0 | $15.30M | $15.25M | $15.20M | $15.15M | $0 | $31.4K | $280.0K | $15.24M | $15.20M | $15.15M |
| Long-term debt | - | - | $0 | $0 | $0 | $0 | $15.10M | $15.00M | $15.00M | $0 | $0 | $0 |
| Total debt | - | - | $15.30M | $15.25M | $15.20M | $15.15M | $15.10M | $15.03M | $15.28M | $15.24M | $15.20M | $15.15M |
| Total liabilities | $8.16M | $9.66M | $24.33M | $27.81M | $28.56M | $29.67M | $29.60M | $33.60M | $32.22M | $27.73M | $27.88M | $28.53M |
| Shareholders' equity | $35.22M | $37.89M | $42.16M | $44.25M | $49.24M | $55.29M | $63.60M | $71.00M | $85.10M | $98.31M | $113.42M | $119.80M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.12M | -$4.59M | -$5.11M | -$5.30M | -$7.02M | -$8.56M | -$12.47M | -$12.04M | -$7.97M | -$13.22M | -$9.97M | $500.4K |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | - | $0 |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | - | $500.4K |
| Investing cash flow | $0 | -$23.1K | $0 | $16.00M | $25.00M | -$554.1K | $7.29M | -$1.56M | $5.26M | -$18.24M | -$30.38M | $0 |
| Financing cash flow | $9.7K | -$15.30M | $71.1K | $0 | $120.7K | $0 | $1.00M | $7.8K | -$197.4K | $0 | $18.2K | -$1.01M |
| Stock-based compensation | $1.11M | $1.64M | -$987.6K | $1.09M | $2.58M | $196.6K | $2.22M | $1.26M | $3.23M | $1.94M | $1.55M | -$800.3K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.45 | 4.91 | 2.72 | 2.58 | 2.72 | 2.86 | 6.49 | 5.59 | 6.80 | 4.55 | 6.50 | 6.64 |
| Debt to equity | - | - | 0.36 | 0.34 | 0.31 | 0.27 | 0.24 | 0.21 | 0.18 | 0.16 | 0.13 | 0.13 |
Source: XBRL data Aldeyra Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ALDX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ALDX | - | - | -$19.13M | - | $38.9M |
| HROW | $303.25M | +21.3% | -$28.49M | -9.4% | $1.03B |
| OCUL | $50.38M | -9.7% | -$326.81M | -648.6% | $1.50B |
| TARS | $682.20M | +86.3% | -$702.23M | -102.9% | $3.49B |
| KALA | $0 | - | -$26.98M | - | $3.4M |
| OCGN | $4.41M | +8.8% | -$67.85M | -1537.4% | $327.4M |
| OTLK | $1.41M | - | -$62.42M | -4416.2% | $111.1M |
ALDX FAQ
5 questionsIs ALDX profitable?
No. Aldeyra Therapeutics Inc. reported a net loss of $19.13M for the twelve months ended Sep 30, 2026.How much cash and debt does ALDX have?
Aldeyra Therapeutics Inc. reported $40.97M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ALDX earnings per share?
Diluted earnings per share were -$0.31 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did ALDX last report financial results?
The latest statements here come from Aldeyra Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this ALDX financial data come from?
Quantisnow builds these statements from the structured XBRL data Aldeyra Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.